HHS Secretary Tom Price calls for health IT that works for clinicians and better interoperability.
While investments in investigational lupus agents appear to be heating up, late-stage clinical failure continues to be a major hurdle to market entry.
AbbVie's Humira tops the list, according to data compiled by EvaluatePharma.
The market for health data and technology is growing, but the industry must also address concerns about privacy, standards, and diversity.
Express Scripts-Anthem deal highlights profitability for PBMs; Sarepta CEO steps down; study says NHS cancer drug fund was ineffective
Sandoz counsel argued that Amgen's position "wrongly delays the marketing of every biosimilar."
Novartis, Kaiser, and Qualcomm partner on heart-failure pilot; Novartis and GSK disclose DTC plans; cancer-treatment hype can be negative for patients
GSK warns Advair generic competition may affect business in 2017; Lilly plans to meet FDA about baricitinib; FDA warns companies selling 'illegal' products
Makers of biosimilars have targeted a few of the top-selling autoimmune drugs. Get ready for some of the highest-stakes pricing and access skirmishes in recent pharma history.
The research found a reduction in utilization of medications used to treat depression, nausea, and psychosis when looking at data for Medicaid beneficiaries.
Sanofi sues Mylan over anticompetitive practices; Anthem to drop Express Scripts; GSK chief digital officer says advertisers should focus on fewer publishers
Here you'll find everything you need to know from MM&M's April 2017 issue, including our DTC report, our deep dive into respiratory drugs, and more.
The Canadian contact lens etailer partnered with a new technology vendor to look beyond its direct click-to-conversions.
QuintilesIMS partners with Salesforce; the E.U. to decide on new EMA location by June; drugmakers boost lobbying dollars in Q1
Josephine Martin was previously EVP of public affairs at PhRMA.
Teva launches branded competitor to GSK's Advair; Valeant prices psoriasis drug at $3,500 per month; overseas drug importation would save money, op-ed argues
Tesaro discloses price for new drug that differs from FDA-approved dosage; uniQure discontinues Glybera; O'Reilly leaves Fox
This is likely due, in part, to the increasingly complex nature of new specialty drugs.
- Five things for pharma marketers to know: Monday, April 24, 2017
- Five things for pharma marketers to know: Tuesday, April 25, 2017
- Drugmakers battle for slice of Humira's billions
- Five things for pharma marketers to know: Wednesday, April 26, 2017
- Five things for pharma marketers to know: Thursday, April 27, 2017
MM&M honors 40 upstarts and veteran innovation gurus.
For the first time MM&M honors a group of 10 agency execs.